Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 156

Sort by

Sort Order Select

Journal Articles

Sustained Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Discriminates Patients with Sustained Negative Minimal Residual Disease

Blood (2023) 142 (Supplement 1): 1958.

https://doi.org/10.1182/blood-2023-179452

Published: 2023

Journal Articles

Light Chain Amyloidosis Plasma Cells Show Specific Chromatin Accessibility and Transcriptome

Blood (2023) 142 (Supplement 1): 4676.

https://doi.org/10.1182/blood-2023-185614

Published: 2023

Journal Articles

Clinical Significance of Measurable Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Chimeric Antigen Receptor (CAR) T Cells and T-Cell Engagers (TCE)

Aintzane Zabaleta, Noemi Puig, Maria Teresa Cedena Romero, Jose J Perez, Cristina Moreno, Luis-Esteban Tamariz-Amador, Paula Rodriguez Otero, Veronica Gonzalez-Calle, Lucia Lopez Corral, Beatriz Rey-Búa, Borja Puertas Martínez, Fatima Miras, Jose Sanchez-Pina, Nieves Lopez, Joaquin Martinez-Lopez, Maria Victoria Mateos, Jesus San-Miguel, Bruno Paiva

Blood (2023) 142 (Supplement 1): 94.

https://doi.org/10.1182/blood-2023-185980

Published: 2023

Journal Articles

A CD38/CD28xCD3 Trispecific T-Cell Engager (TCE) As a Potentially Active Agent in Multiple Myeloma Patients Relapsed and/or Refractory (RRMM) to Anti-CD38 Monoclonal Antibodies (mAbs)

Aintzane Zabaleta, Laura Blanco, Peter Kim, Kamlesh Bisht, Hongfang Wang, Helgi J. Van de Velde, Marta Lasa, Luis-Esteban Tamariz-Amador, Paula Rodriguez Otero, Jesús San Miguel, Bruno Paiva, Esperanza Martín-Sánchez

Blood (2023) 142 (Supplement 1): 1921.

https://doi.org/10.1182/blood-2023-182150

Published: 2023

Journal Articles

Minimally Invasive Assessment of Measurable Residual Disease (MRD) in Multiple Myeloma (MM)

Blood (2023) 142 (Supplement 1): 339.

https://doi.org/10.1182/blood-2023-186916

Published: 2023

Journal Articles

Biological and Clinical Significance of Undetectable Circulating Tumor Cells (CTCs) in Patients (Pts) with Multiple Myeloma (MM)

Blood (2023) 142 (Supplement 1): 646.

https://doi.org/10.1182/blood-2023-186411

Published: 2023

Journal Articles

Isolated and Dynamic Peripheral Blood Residual Disease Status Characterized By Mass Spectrometry Predicts Outcome in Patients with High Risk Smoldering Multiple Myeloma Treated in the GEM-CESAR Trial

Blood (2023) 142 (Supplement 1): 645.

https://doi.org/10.1182/blood-2023-182964

Published: 2023

Journal Articles

A CD38/CD28xCD3 Trispecific T-Cell Engager (TCE) As a Potentially Active Agent for the Treatment of Older Patients with Acute Myeloid Leukemia (AML)

Aintzane Zabaleta, Esperanza Martín-Sánchez, Laura Blanco, Peter Kim, Kamlesh Bisht, Hongfang Wang, Helgi J. Van de Velde, Tomas Jelinek, Catia Simoes, Felipe Prosper, Jesus San-Miguel, David Martinez-Cuadron, Pau Montesinos, Bruno Paiva

Blood (2023) 142 (Supplement 1): 4178.

https://doi.org/10.1182/blood-2023-184797

Published: 2023

Journal Articles

30-Minute Infusion of Isatuximab in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Results of a Phase 1b Study

Enrique M Ocio, Aurore Perrot, Philippe Moreau, Maria-Victoria Mateos, Sara Bringhen, Joaquin Martinez-Lopez, Lionel Karlin, Igor Wolfgang Blau, Song-Yau Wang, Maurizio Martelli, Corina Oprea, Yvonne Dong, Ercem Kodas, Jesus San Miguel

Blood (2023) 142 (Supplement 1): 6717.

https://doi.org/10.1182/blood-2023-175020

Published: 2023

Journal Articles

Symptoms, Functioning, and Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab: Updated Patient-Reported Outcomes from the Phase 1/2 MonumenTAL-1 Study

Blood (2023) 142 (Supplement 1): 6711.

https://doi.org/10.1182/blood-2023-189151

Published: 2023

Journal Articles

Clinical Outcomes of Subsequent Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 MonumenTAL-1 Study

Blood (2023) 142 (Supplement 1): 2007.

https://doi.org/10.1182/blood-2023-182330

Published: 2023

Journal Articles

Analysis of Peripheral Blood and Bone Marrow Residual Disease Dynamics during Intensive Treatment and Maintenance in Patients with Multiple Myeloma Included in the GEM12MENOS65 and GEM14MAIN Clinical Trials

Blood (2023) 142 (Supplement 1): 3324.

https://doi.org/10.1182/blood-2023-184837

Published: 2023

Journal Articles

Updated Results of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies: Results of the Phase 1/2 MonumenTAL-1 Study

Andrzej J Jakubowiak, Sebastien Anguille, Lionel Karlin, Ajai Chari, Carolina Schinke, Leo Rasche, Jesus San-Miguel, Michela Campagna, Brandi W Hilder, Tara J Masterson, Xiang Qin, Thomas Renaud, Jaszianne Tolbert, Deeksha Vishwamitra, Sheri Skerget, Philippe Moreau

Blood (2023) 142 (Supplement 1): 3377.

https://doi.org/10.1182/blood-2023-187242

Published: 2023

Journal Articles

Comprehensive Characterization of the Bone Marrow Microenvironment Transcriptional Remodeling in the Progression from MGUS to Smoldering and Multiple Myeloma

Blood (2023) 142 (Supplement 1): 88.

https://doi.org/10.1182/blood-2023-178534

Published: 2023

Journal Articles

Trial in Progress: A Phase 2 Study of Linvoseltamab for the Treatment of High-Risk Smoldering Multiple Myeloma (LINKER-SMM1)

Paula Rodriguez Otero, Maria-Victoria Mateos, Oluwaseun Aina, Arijit Sinha, Andrew J Steele, Anasuya Hazra, Karen Rodriguez Lorenc, Glenn S. Kroog, Shawn M Sarkaria, Jesus San Miguel

Blood (2023) 142 (Supplement 1): 3393.

https://doi.org/10.1182/blood-2023-179356

Published: 2023

Journal Articles

Longitudinal Screening of Mutant Hematopoietic Progenitor Cells (HPC) in Multiple Myeloma (MM) and Its Association with Secondary Primary Malignancies (SPM)

Blood (2023) 142 (Supplement 1): 533.

https://doi.org/10.1182/blood-2023-185737

Published: 2023

Journal Articles

Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma

Blood (2023) 142 (18): 1518–1528.

https://doi.org/10.1182/blood.2022019531

Published: 2023

Journal Articles

Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study

Blood (2023) 142 (Supplement 1): 2011.

https://doi.org/10.1182/blood-2023-180013

Published: 2023

Journal Articles

Sequential Scmultiomics of In Vivo CAR-T Cells Allows Characterization of Transcriptional Differences between Patients, and Identifies IL10 As a Potential Mechanism of Resistance to CAR-T Cells in MM

Blood (2023) 142 (Supplement 1): 3433.

https://doi.org/10.1182/blood-2023-182887

Published: 2023

Journal Articles

Data-Driven Multiparameter Flow Cytometry (MFC) Classification of Blast Differentiation in Elderly Patients with Acute Myeloid Leukemia (AML)

Blood (2023) 142 (Supplement 1): 1571.

https://doi.org/10.1182/blood-2023-180646

Published: 2023

NARROW

Sustained Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Discriminates Patients with Sustained Negative Minimal Residual Disease

Light Chain Amyloidosis Plasma Cells Show Specific Chromatin Accessibility and Transcriptome

Clinical Significance of Measurable Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Chimeric Antigen Receptor (CAR) T Cells and T-Cell Engagers (TCE)

A CD38/CD28xCD3 Trispecific T-Cell Engager (TCE) As a Potentially Active Agent in Multiple Myeloma Patients Relapsed and/or Refractory (RRMM) to Anti-CD38 Monoclonal Antibodies (mAbs)

Minimally Invasive Assessment of Measurable Residual Disease (MRD) in Multiple Myeloma (MM)

Biological and Clinical Significance of Undetectable Circulating Tumor Cells (CTCs) in Patients (Pts) with Multiple Myeloma (MM)

Isolated and Dynamic Peripheral Blood Residual Disease Status Characterized By Mass Spectrometry Predicts Outcome in Patients with High Risk Smoldering Multiple Myeloma Treated in the GEM-CESAR Trial

A CD38/CD28xCD3 Trispecific T-Cell Engager (TCE) As a Potentially Active Agent for the Treatment of Older Patients with Acute Myeloid Leukemia (AML)

30-Minute Infusion of Isatuximab in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Results of a Phase 1b Study

Symptoms, Functioning, and Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab: Updated Patient-Reported Outcomes from the Phase 1/2 MonumenTAL-1 Study

Clinical Outcomes of Subsequent Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 MonumenTAL-1 Study

Analysis of Peripheral Blood and Bone Marrow Residual Disease Dynamics during Intensive Treatment and Maintenance in Patients with Multiple Myeloma Included in the GEM12MENOS65 and GEM14MAIN Clinical Trials

Updated Results of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies: Results of the Phase 1/2 MonumenTAL-1 Study

Comprehensive Characterization of the Bone Marrow Microenvironment Transcriptional Remodeling in the Progression from MGUS to Smoldering and Multiple Myeloma

Trial in Progress: A Phase 2 Study of Linvoseltamab for the Treatment of High-Risk Smoldering Multiple Myeloma (LINKER-SMM1)

Longitudinal Screening of Mutant Hematopoietic Progenitor Cells (HPC) in Multiple Myeloma (MM) and Its Association with Secondary Primary Malignancies (SPM)

Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma

Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study

Sequential Scmultiomics of In Vivo CAR-T Cells Allows Characterization of Transcriptional Differences between Patients, and Identifies IL10 As a Potential Mechanism of Resistance to CAR-T Cells in MM

Data-Driven Multiparameter Flow Cytometry (MFC) Classification of Blast Differentiation in Elderly Patients with Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only